Viral microRNAs responsible for causing AIDS-related cancer

January 13, 2014

For the first time, scientists and engineers have identified a critical cancer-causing component in the virus that causes Kaposi's sarcoma, the most common cancer among HIV-infected people. The discovery lays the foundation for developing drugs that prevent Kaposi's sarcoma and other related cancers.

"The mechanism behind the Kaposi's -associated herpesvirus (KSHV) that causes to become malignant is not well understood despite two decades of intensive studies," said S. J. Gao, Ph.D., professor of molecular microbiology and immunology at the Keck School of Medicine of the University of Southern California (USC) and principal investigator of the study. "This is the first time that a viral factor has been shown to be required for KSHV-induced malignant transformation. We have identified a mechanism by which these tiny viral molecules cause the cells to become malignant."

Distinguished by dark lesions on the skin, Kaposi's sarcoma most commonly develops in people who are infected with KSHV and also have compromised immune systems. Although many people infected with KSHV never show any symptoms, Kaposi's sarcoma is a persistent problem in areas where HIV infection is high and access to HIV therapy is limited. More than 90 percent of the population in some areas of Africa shows signs of KSHV infection, according to the American Cancer Society.

Gao and colleagues from the University of Texas at San Antonio (UTSA) and University of Texas Health Science Center at San Antonio studied KSHV using a rat stem cell model they developed in 2012. Until then, researchers had been unable to study the virus because most healthy cells, once infected with KSHV, died before turning into .

In this study, which appears in the Dec. 26 edition of the peer-reviewed journal PLOS Pathogens, the team identifies a cluster of viral microRNA molecules that are necessary to transform healthy cells into cancerous ones. When this microRNA cluster was suppressed, the cells died after they were infected with KSHV. Flipping the switch and turning the cluster back "on," however, allowed the cells to stay alive and become malignant when infected with the virus.

Using advanced genomic methods, the researchers also found that the microRNAs target the IκBα protein and the NF-κB cellular pathway, both of which are associated with development.

"Our results suggest that this cluster of KSHV microRNAs and their regulated NF-κB pathway may be potential targets for new therapeutics of KSHV-related cancers," said Gao, who is also a member of the USC Norris Comprehensive Cancer Center. "Several of the microRNAs appear to have redundant functions, so targeting their common pathways might be a more feasible approach. It would be interesting to test them in the KSHV-induced Kaposi's sarcoma model."

Explore further: Study identifies trigger for alternate reproduction of HIV-related cancer virus

Related Stories

Study identifies trigger for alternate reproduction of HIV-related cancer virus

April 17, 2012
A research team led by Children's National Medical Center has identified a trigger that causes latent Kaposi's sarcoma-associated herpesvirus (KSHV) to rapidly replicate itself. KSHV causes Kaposi's sarcoma, primary effusion ...

KS-herpesvirus induces reprogramming of lymphatic endothelial cells to invasive mesenchymal cells

December 14, 2011
Kaposi's sarcoma herpesvirus (KSHV) is an etiological agent for Kaposi's sarcoma and two other rare lymphoproliferative malignancies, and it is the most common cancer in HIV-infected untreated individuals. Researchers at ...

Searching for therapeutic synergy in primary effusion lymphoma

May 1, 2013
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...

Viral replication impedes the efficacy of a targeted therapy against virus-induced lymphomas

April 3, 2012
Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.